> Back to EJC

2016 editions

  • December 2016
    Joao Incio on mechanisms to explain why obesity promotes cancer.
  • November 2016
    Mike Stratton on how mutational changes in a cancer genome can point to the cause of the cancer.
  • October 2016
    Ruth Muschel on a new target for treatments for colorectal cancer.
  • September 2016
    Freddie Hamdy on the effectiveness of treatments for prostate cancer.
  • August 2016
    Moshe Oren discusses the effects of the microenvironment on cancer cells.
  • July 2016
    Richard Gilbertson on the 'bad luck hypothesis' for the cause of cancer.
  • June 2016
    Key advances in clinical trials.
  • May 2016
    Mark Lemmon on the underlying biochemistry of cancer.
  • April 2016
    Roger Stupp on using alternating electric fields as treatment.
  • March 2016
    Charlotte Vrinten on public perception of deaths from cancer.
  • February 2016
    Guillermo Garcia-Manero on myelodysplastic syndromes (MDS).
  • December 2015/January 2016
    Nazneen Rahman on germline genetic screening in ovarian cancer.

> All 2015 Editions

> All 2014 Editions

> All 2013 Editions

> All 2012 Editions

> All 2011 Editions

EJC News Focus – May 2015

Loading EJC News Focus video

How to overcome drug resistance

Strategies for overcoming resistance need to be incorporated into drug development from the outset, according to Paul Workman (The Institute of Cancer Research, London). Choosing targets at the heart of the mechanism for clonal evolution of cancer might reduce the chance of tumour cells developing resistance to new agents.

Giving the keynote lecture at the 13th International Congress on Targeted Anticancer Therapies (Paris, France; 2-4 March 2015), he said that chaperone proteins such as HSP90 have an impact on multiple signalling pathways in cancer, and might be suitable targets. Effective inhibition of HSP90 could reduce the chance of resistance developing.

In EJC News Focus, Paul Workman describes progress so far to Helen Saul.